Assertio Therapeutics (ASRT) Tops Q3 EPS by 7c

Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.03, $0.07 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $28.7 million versus the consensus estimate of $28.87 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• nCino (NCNO) Reiterated at Market Outperform by Citizens on New Pricing Plan